
No Stock Yet
Changchun Hi-Tech (000661): Overcoming low performance and multiple business layouts to help long-term development
Changchun Hi-Tech (000661) 2023 Quarterly Report Review: Jinsai's performance fluctuates slightly in the short term, and the long-term trend is positive
Changchun Hi-Tech (000661): Multiple factors put pressure on Q1 performance and multi-track layout is expected to drive continued growth in future performance
Changchun Hi-Tech (000661): Short-term performance is under pressure, and it is optimistic that the new patients in 23Q2 will reach an inflection point
Changchun Hi-Tech (000661): Multiple Factors Influence Current Performance, Divestment of Real Estate to Focus on Biomedical Business
Changchun Hi-Tech (000661): Growth hormone is under short-term pressure and is optimistic that it will recover quarterly throughout the year
Changchun Hi-Tech (000661) 2023 Quarterly Review Report: The epidemic disrupted the pace of operations and led to poor performance in the first quarter and I'm optimistic about this year's subsequent recovery
Changchun Hi-Tech (000661): The 2Q inflection point can be expected to build a new blueprint for new product groups
Changchun Hi-Tech (000661): Quarterly earnings run out, opportunities worth focusing on
Changchun Hi-Tech (000661) Review Report: Long-acting Growth Hormone PEG Achieves Continuous Improvement in the Overall Competitiveness of Self-Producing Companies
Loading...
No Stock Yet